News & Events

Disc Medicine Announces Oral Presentation on Bitopertin at the 63rd American Society of Hematology Annual Meeting

CAMBRIDGE, Mass. (November 11, 2021) – Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases, today announced that the company and its collaborators at Boston Children’s Hospital have been selected to give an oral presentation at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in Atlanta, GA on December 11-14, 2021. Disc will present data from studies of bitopertin, the company’s orally available glycine transporter 1 (GlyT1), in preclinical models of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP).

Details of the presentation are as follows:

Abstract Number: 760

Title: Proof of Mechanism Studies with Bitopertin, a Selective Glycine Transporter 1 Inhibitor Under Development for the Treatment of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLPP)

Date / Time: Monday, December 13, 2021: 5:15 PM
Session: 102. Iron Homeostasis and Biology: Disorders of Iron and Heme and Novel treatments
Presenter: Paul Schmidt

Full abstract currently available through the ASH conference website: https://ash.confex.com/ash/2021/webprogram/Paper150441.html

###

About Bitopertin

Bitopertin is designed to be an oral, potent, and selective inhibitor of GlyT1, a key membrane transporter required to supply developing red blood cells with sufficient glycine to support erythropoiesis. Glycine is an essential component of heme and by limiting glycine uptake in newly forming red blood cells, bitopertin is designed to modulate heme biosynthesis to potentially treat a range of hematologic disorders associated with the biosynthesis of heme and hemoglobin. Bitopertin has been evaluated in a comprehensive clinical program focused on certain neurological disorders conducted by Roche in over 4,000 individuals, which demonstrated the activity of bitopertin as a GlyT1 inhibitor and suppressor of heme biosynthesis. In preclinical studies in human and animal models of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), bitopertin was shown to significantly decrease PPIX, a toxic intermediate of heme synthesis that is the underlying cause of the disease. Disc Medicine is planning to develop bitopertin as a potential treatment for patients with EPP and XLP as well as a range of other hematologic diseases. Bitopertin is an experimental agent and is not approved for use as a therapy in any jurisdiction worldwide.

About Disc Medicine

Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. We are building a portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. For more information, please visit www.discmedicine.com.

Media Contact

Peg Rusconi
Verge Scientific Communications
prusconi@vergescientific.com

More News

Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting

WATERTOWN, Mass. (December 13, 2022) – Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments...

Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting

CAMBRIDGE, Mass. (November 3, 2022) – Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments...

Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)

WATERTOWN, Mass. (October 31, 2022) – Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments...

Disc Medicine Initiates BEACON, a Phase 2 Clinical Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)

WATERTOWN, Mass. (August 10, 2022) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutic candidates...

Gemini Therapeutics and Disc Medicine Announce Merger Agreement

WAYLAND, Mass. and WATERTOWN, Mass. (August 10, 2022) – Gemini Therapeutics, Inc. (Nasdaq: GMTX) (“Gemini”) and Disc Medicine, Inc. (“Disc”), a privately-held,...

Disc Medicine Initiates Phase 1b/2 Clinical Study of DISC-0974 in Myelofibrosis Patients with Severe Anemia

CAMBRIDGE, Mass. (June 23, 2022) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutic candidates...

Disc Medicine Presents Positive Results from Phase 1 Clinical Study of DISC-0974 in Healthy Volunteers at the 2022 EHA Annual Congress

WATERTOWN, Mass. (June 10, 2022) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...

Disc Medicine Announces Presentation of Clinical Data from First-in-Human Phase 1 Study of DISC-0974 at European Hematology Association (EHA) 2022 Congress

WATERTOWN, Mass. (May 16, 2022) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...

Disc Medicine Appoints Jay T. Backstrom, M.D., M.P.H., to its Board of Directors and Rahul Khara, Pharm.D., J.D., as General Counsel

CAMBRIDGE, Mass. (January 4, 2022) - Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for...

Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases

CAMBRIDGE, Mass. (September 2, 2021) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for...

Disc Medicine Appoints Will Savage, MD, PhD as Chief Medical Officer and Jonathan Yu as Chief Business Officer and Expands Scientific Leadership with Key Hires to Advance Clinical-Stage Pipeline

CAMBRIDGE, Mass. (August 23, 2021) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for...

Disc Medicine Initiates Phase 1 Clinical Study of DISC-0974, a First-In-Class Inhibitor of Hemojuvelin (HJV) in Development for the Treatment of Anemia of Inflammation

CAMBRIDGE, Mass. (July 28, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapies for the...

Disc Medicine Expands Hematology Pipeline with Worldwide Licensing Agreement for Bitopertin, a First-in-Class Modulator of Heme Synthesis

CAMBRIDGE, Mass. (May 27, 2021) – Disc Medicine, Inc. announced today that it has entered into an exclusive worldwide licensing agreement with...

Disc Medicine to Present at the European Hematology Association (EHA) 2021 Virtual Congress

CAMBRIDGE, Mass. (May 24, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...

Disc Medicine to Present at the Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass. (May 21, 2021) – Disc Medicine, a company dedicated to the discovery and development of novel therapeutic candidates for serious...

Disc Medicine Appoints William White to its Board of Directors

CAMBRIDGE, Mass. (January 13th, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...

Disc Medicine to Present at the Virtual 62nd American Society of Hematology Annual Meeting

CAMBRIDGE, Mass. (December 2, 2020) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...

Disc Medicine to Present at the Piper Sandler 32nd Annual Healthcare Conference

CAMBRIDGE, Mass. (November 23, 2020) – Disc Medicine, a hematology company dedicated to the discovery and development of novel therapeutic candidates for...

Disc Medicine Expands Scientific Advisory Board with Leading Experts in Hepcidin Biology

Tomas Ganz, MD, PhD and Elizabeta Nemeth, PhD to Join Disc Medicine Scientific Advisory Board Cambridge, Mass. – October 13, 2020 –...

Disc Medicine to Present at Citi's 15th Annual BioPharma Virtual Conference

Cambridge, Mass. – September 8, 2020 – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates...

Disc Medicine Expands Leadership Team with Industry Veterans to Advance Hepcidin Modulating Therapies Toward the Clinic

Jonathan Yu Named Senior Vice President of Corporate Strategy William Savage, MD, PhD Appointed Vice President of Clinical Development

John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer

Cambridge, Mass. – January 28, 2020 – Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that...

Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production

Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic...

Disc Medicine Expands Pipeline Focused on Hepcidin Pathway

Enters into exclusive agreement with AbbVie for series of Hemojuvelin Antagonist Monoclonal Antibodies Cambridge, Mass. – October 29, 2019 – Disc Medicine,...

Introducing Disc Medicine, a New Hematology Company

Introducing Disc Medicine – we are a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell productions...